WHC is still in active development. Read this to understand our approach.
depiction of KJFMBFZCATUALV-UHFFFAOYSA-N.svg
isomerdesign

Phenolphthalein

Check on isomerdesign

pubchem

Phenolphthalein

Check on pubchem

drugmap

Phenolphthalein

Check on drugmap

Data

InChI: InChI=1S/C20H14O4/c21-15-9-5-13(6-10-15)20(14-7-11-16(22)12-8-14)18-4-2-1-3-17(18)19(23)24-20/h1-12,21-22H

Synonyms: component of Agoral,Spectrum3_000888,SMP1_000235,NCGC00254039-01,P0094,Purgen,UNII-6QK969R2IF,FemiLax,5-18-04-00188 (Beilstein Handbook Reference),PHENOLPHTHALEIN [HSDB],BRD-K19227686-001-12-9, Phthalimetten,3,3-bis (4-hydroxyphenyl)-2-benzofuran-1-on,3,3-Bis(4-hydroxyphenyl)phthalide,Phenolphthalein Solution, Alcoholic 1.0%, 3,3-Bis(4-hydroxyphenyl)-1(3H)-isobenzofuranone,KBioGR_001383,Laxin,AC-14431,1(3H)-Isobenzofuranone, 3,3-bis(4-hydroxyphenyl)-, Lilo,NCGC00023694-05,DSSTox_GSID_21125,Alophen,NSC-215214,AI3-09081, Fenolftalein,component of Feen-A-Mint Pills,PHENOLPHTHALEIN [MI], Purgen,.alpha., .alpha.-Di(p-hydroxyphenyl)phthalide,PHENOLPHTHALIN [MI],SR-01000000112,DSSTox_RID_75956,Phenolphthalein (263 degrees C) Melting Point Standard,Phenolphthalein, ACS reagent,PHENOLPHTHALEIN [INN],NCGC00018200-03,Phenolphthalein, JIS special grade, >=98.0%,P0702,Phenolphthalein,yellow,Euchessina, Espotabs,Spectrum2_001279,Spectrum5_001268, Fenolftaleina,BRD-K19227686-001-02-0,SBI-0051481.P003,CHEMBL63857,EN300-92962,component of Correctol (Salt/Mix),Phenolphthalein, pH indicator, Laxin,BBL002030,PHENOLPHTHALEIN [EP MONOGRAPH],3,3-bis(4-hydroxyphenyl)-3-hydroisobenzofuran-1-one,Doxan (Salt/Mix), Phenolphtaleine,Phenolphthaleine,Phenolphthaleinum,KBio2_001557, Trilax, Colax,Z57233591,Phillips Gelcaps,3,3-Bis(p-hydroxyphenyl)phthalide, Evac-Q-Tabs,HMS2236I09, Lax-Pills,Fenolftalein,Phenolphthalein solution R1, Dihydroxyphthalophenone,Phenolphthalein [USP:INN:BAN],HY-D0211,CCRIS 6266,Phenolphthalein, SAJ first grade, >=97.0%,Phenophthalein,Phenolphthaleinum [INN-Latin],NCI-C55798,HMS1920H04,Purga,Fenolftaleina,Trilax,3,3-Bis(4-hydroxyphenyl)-1(3H)-isobenzofuranone,Phenolphthalein (INN),EU-0082600,NCGC00023694-06,3,3-Bis(4-hydroxyphenyl)isobenzofuran-1(3H)-one,Phenolphtaleine,SPBio_001278,Feen-A-Mint Gum,Phenolphthalein ACS reagent,Phenolphthalein, 0.5% w/v in alcohol,NSC 10464,Tox21_202219, Ex-Lax,PHENOLPHTHALEIN [IARC],Spulmako-lax,MLS000069592,cid_4764,3, 3-Bis(p-hydroxyphenyl)-1(3H)-isobenzofuranone,Phenolax,Agoral (Salt/Mix),Phenolphtaleine [INN-French],Agoral,EC 201-004-7,Phenolphthalein solution, 0.1 N,Opera_ID_1337,NCGC00018200-08,NSC10464,Phenolphthaleinum, Evac-Q-Kit, Chocolax,Feen-A-Mint Laxative Mints,DSSTox_CID_1125,ZINC3831317,Espotabs,alpha-Di(p-hydroxyphenyl)phthalide,Phenolphthalein, puriss., meets analytical specification of Ph??Eur., BP, 98-101% (calc. to the dried substance),IDI1_000929,NCGC00259768-01,KBio1_000929,P0700,F0921-4309, Medilax,Phenolphthalein,(S),BP-30100, Doxidan, Purga,SMR000059015,Fenolftaleina [INN-Spanish],NCGC00023694-03,Spectrum_001077,Lax-Pills, Feen-A-Mint Gum,Spectrum4_000982,alpha-(p-Hydroxyphenyl)-alpha-(4-oxo-2,5-cyclohexadien-1-ylidene)-o-toluic acid,PHENOLPHTHALEIN [MART.],STK029876,3,3-Bis(4-hydroxyphenyl)-2-benzofuran-1(3H)-one,NSC757271,PHENOLPHTHALEIN,WHITE [VANDF],NSC-757271,WLN: T56 BVO DHJ D- D-/R DQ 2,Phenolphthalein,white,Pharmakon1600-01500480, 1(3H)-Isobenzofuranone, 3,3-bis(4-hydroxyphenyl)-, 3,3-Bis(4-hydroxyphenyl)phthalide,H12020,NCGC00023694-07,BSPBio_002518,3,3-bis(4-hydroxyphenyl)-2-benzofuran-1-one,Medilax,NCGC00018200-06,HMS2091P06, Evac-Q-Kwik,NCGC00018200-07,Tox21_300282,PHENOLPHTHALEIN [VANDF],Modane Plus (Salt/Mix), Laxogen,KBio2_004125,PHENOLPHTHALEIN [WHO-DD],CAS-77-09-8, Phthalin,D05456,3,3-bis(4-hydroxyphenyl)isobenzofuran-1-one,NCGC00018200-09,Q187921, FemiLax,Phthalide 3,3,-bis(p-hydroxyphenyl)-, Alophen,component of Correctol, Evac-U-Gen,BIDD:ER0202,Phenolphthalein,Laxogen,3,3-bis(4-hydroxyphenyl)-1,3-dihydro-2-benzofuran-1-one,SCHEMBL27670,AMY37148,PHENOLPHTHALEIN [INCI],SR-01000000112-2,NCGC00018200-04,BCBcMAP01_000174,Phenolphthalein pH indicator solution,CHEBI:34914,Tox21_110838_1,NCGC00018200-05,NSC-10464,HMS502O11,3,3-Bis-(4-hydroxy-phenyl)-3H-isobenzofuran-1-one,MFCD00005913, Koprol,6QK969R2IF,AB00052070_15,Dihydroxyphthalophenon,Dioxy-triphenylcarbinol-o-carbonsaeureanhydrid, Phenolax, Correctol,phenolphthalein,NCGC00018200-01,PHENOLPHTHALEIN, WHITE,AKOS000493033,NCGC00018200-02, Phenophthalein,SPECTRUM1500480,P0701,BDBM50077844,Koprol,Dihydroxyphthalophenone,HSDB 4161, Spulmako-lax,Fenolftalein [Czech],Evac-Q-Kwik,Phenolphthalein solution,NCGC00023694-04,KBio2_006693,Phenolphthalein solution, 1 % (w/v), pH 7.8-10.0,Phenolphthalein, p.a., ACS reagent,EINECS 201-004-7,FGT,s5395,DivK1c_000929, 77-09-8,FT-0659094,HMS3374P06,Colax,component of Feen-A-Mint Pills (Salt/Mix),Q-201555,Evac-U-Gen,NCGC00018200-12, Euchessina,Modane (TN),Phthalin,KBioSS_001557,NCGC00018200-10, Purgophen,Phenolphthalein solution, 0.1 % (w/v), pH 7.8-10.0,Laxcaps (Salt/Mix),3,3-Bis(4-hydroxyphenyl)-2-benzofuran-1(3H)-one #,Phenolphthalein solution, 0.5 wt. % in ethanol: water (1:1),DTXSID0021125, Phillips Gelcaps,NSC215214,Phenolphthalein, United States Pharmacopeia (USP) Reference Standard,DB04824,3,3-bis(4-hydroxyphenyl)-2-benzofuran-1-on,77-09-8,BRN 0284423,Phthalide 3,-bis(p-hydroxyphenyl)-,1(3H)-Isobenzofuranone,3-bis(4-hydroxyphenyl)-,MLS001148397,PHENPOLPHTHALEIN [VANDF],KBio3_001776,NINDS_000929,Tox21_110838,Phenolphthalein Paper, DAB 6,CS-8152,VS-01000,Doxidan,CCG-39112,Phenolphthalein solution, 0.04 % (w/v), pH 7.8-10.0,Correctol,Phenolphthalein, ACS reagent, reag. Ph. Eur., indicator, 98-102% (calc. to the dried substance), S. No.: 879,Evac-Q-Kit,Phenolphthalein, 2% solution in 95% ethanol,Yellow phenolphthalein,Phthalimetten,phenolphtalein


Estimated data

Solubility: -5.795 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 41.6% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.